| Dr Todd B Whitsitt, MD | |
|
2121 E Harmony Rd, Unit 100, Fort Collins, CO 80528-3401 | |
| (970) 221-1000 | |
| (970) 297-6860 |
| Full Name | Dr Todd B Whitsitt |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 40 Years |
| Location | 2121 E Harmony Rd, Fort Collins, Colorado |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457357824 | NPI | - | NPPES |
| 109333900 | Medicaid | WY | |
| P00970465 | Other | CO | MEDICARE RAILROAD |
| 01314814 | Medicaid | CO |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sidney Regional Medical Center | Sidney, NE | Hospital |
| Regional West Medical Center | Scottsbluff, NE | Hospital |
| Poudre Valley Hospital | Fort collins, CO | Hospital |
| Medical Center Of The Rockies | Loveland, CO | Hospital |
| Yuma District Hospital | Yuma, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Poudre Valley Medical Group Llc | 9638208549 | 1605 |
| Poudre Valley Medical Group Llc | 9638208549 | 1605 |
| Poudre Valley Medical Group Llc | 9638208549 | 1605 |
News Archive
Pfizer Inc. announced today that the Phase 3 AXIS 1032 trial (A4061032), studying the investigational compound axitinib in previously treated patients with metastatic renal cell carcinoma (mRCC), has met its primary endpoint, demonstrating that axitinib significantly extended progression-free survival when compared to sorafenib, in the study population.
The National Institutes of Health (NIH) has awarded a five-year, $5.5 million Transformative Research Project (T-R01) Award to fund research into risk factors for spina bifida and related congenital defects in which an area of the affected baby's spine or brain is not fully enclosed.
After Yarly Raygoza attended the drug prevention program at the Boys & Girls Club here last year, she used what she learned to talk a few friends out of using marijuana.
Transgenomic, Inc. today announced that it completed the requirements for CE IVD labeling and has significantly expanded distribution of its SURVEYOR® Scan K-RAS mutation detection kit throughout most of the European Union. The SURVEYOR Scan K-RAS CE IVD kit is a member of Transgenomic's family of mutation detection kits, which features proprietary SURVEYOR endonuclease technology.
› Verified 9 days ago
| Entity Name | Poudre Valley Health Care Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760492714 PECOS PAC ID: 7618880709 Enrollment ID: O20031105000791 |
News Archive
Pfizer Inc. announced today that the Phase 3 AXIS 1032 trial (A4061032), studying the investigational compound axitinib in previously treated patients with metastatic renal cell carcinoma (mRCC), has met its primary endpoint, demonstrating that axitinib significantly extended progression-free survival when compared to sorafenib, in the study population.
The National Institutes of Health (NIH) has awarded a five-year, $5.5 million Transformative Research Project (T-R01) Award to fund research into risk factors for spina bifida and related congenital defects in which an area of the affected baby's spine or brain is not fully enclosed.
After Yarly Raygoza attended the drug prevention program at the Boys & Girls Club here last year, she used what she learned to talk a few friends out of using marijuana.
Transgenomic, Inc. today announced that it completed the requirements for CE IVD labeling and has significantly expanded distribution of its SURVEYOR® Scan K-RAS mutation detection kit throughout most of the European Union. The SURVEYOR Scan K-RAS CE IVD kit is a member of Transgenomic's family of mutation detection kits, which features proprietary SURVEYOR endonuclease technology.
› Verified 9 days ago
| Entity Name | Poudre Valley Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366763260 PECOS PAC ID: 9638208549 Enrollment ID: O20100602000122 |
News Archive
Pfizer Inc. announced today that the Phase 3 AXIS 1032 trial (A4061032), studying the investigational compound axitinib in previously treated patients with metastatic renal cell carcinoma (mRCC), has met its primary endpoint, demonstrating that axitinib significantly extended progression-free survival when compared to sorafenib, in the study population.
The National Institutes of Health (NIH) has awarded a five-year, $5.5 million Transformative Research Project (T-R01) Award to fund research into risk factors for spina bifida and related congenital defects in which an area of the affected baby's spine or brain is not fully enclosed.
After Yarly Raygoza attended the drug prevention program at the Boys & Girls Club here last year, she used what she learned to talk a few friends out of using marijuana.
Transgenomic, Inc. today announced that it completed the requirements for CE IVD labeling and has significantly expanded distribution of its SURVEYOR® Scan K-RAS mutation detection kit throughout most of the European Union. The SURVEYOR Scan K-RAS CE IVD kit is a member of Transgenomic's family of mutation detection kits, which features proprietary SURVEYOR endonuclease technology.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Todd B Whitsitt, MD 2695 Rocky Mountain Ave, Ste 150, Loveland, CO 80538-8702 Ph: (970) 221-1000 | Dr Todd B Whitsitt, MD 2121 E Harmony Rd, Unit 100, Fort Collins, CO 80528-3401 Ph: (970) 221-1000 |
News Archive
Pfizer Inc. announced today that the Phase 3 AXIS 1032 trial (A4061032), studying the investigational compound axitinib in previously treated patients with metastatic renal cell carcinoma (mRCC), has met its primary endpoint, demonstrating that axitinib significantly extended progression-free survival when compared to sorafenib, in the study population.
The National Institutes of Health (NIH) has awarded a five-year, $5.5 million Transformative Research Project (T-R01) Award to fund research into risk factors for spina bifida and related congenital defects in which an area of the affected baby's spine or brain is not fully enclosed.
After Yarly Raygoza attended the drug prevention program at the Boys & Girls Club here last year, she used what she learned to talk a few friends out of using marijuana.
Transgenomic, Inc. today announced that it completed the requirements for CE IVD labeling and has significantly expanded distribution of its SURVEYOR® Scan K-RAS mutation detection kit throughout most of the European Union. The SURVEYOR Scan K-RAS CE IVD kit is a member of Transgenomic's family of mutation detection kits, which features proprietary SURVEYOR endonuclease technology.
› Verified 9 days ago
Dr. Stephen A Treat, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2121 E Harmony Rd, Ste 100, Fort Collins, CO 80528 Phone: 970-221-1000 Fax: 970-297-6844 | |
Dr. David Kindley Cobb, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 2121 E Harmony Rd Unit 380, Fort Collins, CO 80528 Phone: 970-224-0429 | |
Dr. Diana M Breyer, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2121 E Harmony Rd, Suite 300, Fort Collins, CO 80528 Phone: 970-224-9102 Fax: 970-224-9112 | |
Fred H Meyer, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 219 S Sunset St, Fort Collins, CO 80521 Phone: 970-224-2156 Fax: 970-482-6936 | |
Robert A Simmons, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 3702 S Timberline Rd, Fort Collins, CO 80525 Phone: 970-207-9773 Fax: 970-207-1893 | |
Dr. Charles Timothy Johnson, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2121 E Harmony Rd, Unit 100, Fort Collins, CO 80528 Phone: 970-221-1000 Fax: 970-297-6860 | |
Dr. Elizabeth A Yoder, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2637 Midpoint Dr Ste B, Fort Collins, CO 80525 Phone: 970-488-1666 Fax: 970-472-9381 |